These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 17675286)
1. Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. Ueno H; Okusaka T; Ikeda M; Morizane C; Ogura T; Hagihara A; Tanaka T Jpn J Clin Oncol; 2007 Jul; 37(7):515-20. PubMed ID: 17675286 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320 [TBL] [Abstract][Full Text] [Related]
3. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757 [TBL] [Abstract][Full Text] [Related]
4. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Clayton AJ; Mansoor AW; Jones ET; Hawkins RE; Saunders MP; Swindell R; Valle JW Pancreas; 2006 Jan; 32(1):51-7. PubMed ID: 16340744 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Brodowicz T; Wolfram RM; Köstler WJ; Tomek S; Vaclavik I; Steger GG; Teleky B; Függer R; Jakesz R; Zielinski CC Anticancer Drugs; 2000 Sep; 11(8):623-8. PubMed ID: 11081453 [TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993 [TBL] [Abstract][Full Text] [Related]
8. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457 [TBL] [Abstract][Full Text] [Related]
10. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211 [TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma. Bang S; Jeon TJ; Kim MH; Park JY; Park SW; Chung JB; Song SY Pancreatology; 2006; 6(6):635-41. PubMed ID: 17159377 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810 [TBL] [Abstract][Full Text] [Related]
15. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732 [TBL] [Abstract][Full Text] [Related]
16. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814 [TBL] [Abstract][Full Text] [Related]
17. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. Feliu J; Sáenz JG; Jaráiz AR; Castañón C; Cruz M; Fonseca E; Lomas M; Castro J; Jara C; Casado E; León A; Barón MG Cancer Chemother Pharmacol; 2006 Oct; 58(4):419-26. PubMed ID: 16404636 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299 [TBL] [Abstract][Full Text] [Related]
19. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]